Ruxolitinib is effective in the treatment of a patient with refractory T-ALL
T-cell acute lymphoblastic leukemia (T-ALL) is a rare, aggressive T-cell malignancy. Chemotherapy alone cures only 25-45% of the cases, thus, novel treatment agents and strategies are urgently needed. We assessed the efficacy of ruxolitinib in a patient with a cutaneous relapse after allogeneic bloo...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) Editorial |
| Langue: | anglais |
| Publié: |
2021
|
| In: |
eJHaem
Year: 2021, Volume: 2, Numéro: 1, Pages: 139-142 |
| ISSN: | 2688-6146 |
| DOI: | 10.1002/jha2.143 |
| Accès en ligne: | Verlag, kostenfrei, Volltext: https://doi.org/10.1002/jha2.143 Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/jha2.143 
|
| Notes sur l'auteur: | Sonia Jaramillo, Hannah Hennemann, Peter Horak, Veronica Teleanu, Christoph E. Heilig, Barbara Hutter, Albrecht Stenzinger, Hanno Glimm, Benjamin Goeppert, Carsten Müller-Tidow, Stefan Fröhling, Stefan Schönland, Richard F. Schlenk |
| Résumé: | T-cell acute lymphoblastic leukemia (T-ALL) is a rare, aggressive T-cell malignancy. Chemotherapy alone cures only 25-45% of the cases, thus, novel treatment agents and strategies are urgently needed. We assessed the efficacy of ruxolitinib in a patient with a cutaneous relapse after allogeneic blood cell transplantation of a refractory T-ALL with a Janus kinase 3 (JAK3) mutation. In this case report, we were able to show the potential benefit of the JAK inhibitor ruxolitinib in JAK3-mutated refractory T-ALL and emphasize the importance of integrating molecular markers in current treatment decision making for patients with T-ALL. |
|---|---|
| Description: | First published: 04 December 2020 Gesehen am 07.09.2021 |
| Description matérielle: | Online Resource |
| ISSN: | 2688-6146 |
| DOI: | 10.1002/jha2.143 |